Evidence map›Paper›PMID 36275735›Full record

ReviewFrontiers in immunology2022

Possible role of gut microbes and host's immune response in gut-lung homeostasis.

Sonakshi Rastogi, Sneha Mohanty, Sapna Sharma, Prabhanshu Tripathi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Journal of microbiology and biotechnology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Impact of carbapenem-resistantMicrobiology spectrum · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. The Role of Lipid Metabolism Disorders in Rhinitis and Asthma.Combinatorial chemistry & high throughput screening · 2026
    Review
  15. Potential Benefits of Gut Microbiota Modulation in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026
    Article
  16. mSystems · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sonakshi RastogiFood Drug and Chemical Toxicology Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.
Sneha MohantyFood Drug and Chemical Toxicology Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.
Sapna SharmaInstitute of Biosciences and Biotechnology, Shri Ramswaroop Memorial University, Barabanki, Uttar Pradesh, India.
Prabhanshu TripathiFood Drug and Chemical Toxicology Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.
Council of Scientific and Industrial Research · INIndian Institute of Toxicology Research · INShri Ramswaroop Memorial University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vast diversity of microbial communities reside in various locations of the human body, and they are collectively named as the 'Human Microbiota.' The majority of those microbes are found in the gastrointestinal and respiratory tracts. The microorganisms present in the gastrointestinal and the respiratory tracts are called the gut microbiota and the airway microbiota, respectively. These microbial communities are known to affect both the metabolic functions and the immune responses of the host. Among multiple factors determining the composition of gut microbiota, diet has played a pivotal role. The gut microbes possess enzymatic machinery for assimilating dietary fibers and releasing different metabolites, primarily short-chain fatty acids (SCFAs). The SCFAs modulate the immune responses of not only the gut but other distal mucosal sites as well, such as the lungs. Dysbiosis in normal gut flora is one of the factors involved in the development of asthma and other respiratory disorders. Of note, several human and murine studies have indicated significant cross-talk between gut microbiota and lung immunity, known as the gut-lung axis. Here, in this review, we summarize the recent state of the field concerning the effect of dietary metabolites, particularly SCFAs, on the "gut-lung axis" as well as discuss its impact on lung health. Moreover, we have highlighted the role of the "gut-lung axis" in SARS-CoV-2 mediated inflammation. Also, to analyze the global research progress on the gut-lung axis and to identify the knowledge gap in this field, we have also utilized the bibliographic tools Dimension database and VOS viewer analysis software. Through network mapping and visualization analysis, we can predict the present research trend and the possibility to explore new directions.

Indexed as

COVID-19Gastrointestinal MicrobiomeAnimalsDietary FiberFatty Acids, VolatileHomeostasisHumansImmunityLungMiceSARS-CoV-2Dietary FiberFatty Acids, Volatileairway microbiomebibliographic analysisdietgut–lung axisgut microbiomelung immunityshort-chain fatty acids

Identifiers

PMID36275735
PMCPMC9581402
OpenAlexW4301586416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.